Stay Alert for Lybalvi, a New Combo Antipsychotic

January 1

Rx Lybalvi combines the antipsychotic olanzapine with samidorphan, a new opioid antagonist...for schizophrenia or bipolar disorder.

Samidorphan is derived from naltrexone. But so far, using it alone hasn’t panned out for alcohol use disorder or other conditions.

In Lybalvi, the idea is that samidorphan may lessen weight gain from olanzapine...possibly by blocking opioid receptors that regulate appetite.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote